A Study of the Effects of Sitagliptin (MK0431) and Metformin on Incretin Hormone Concentrations (0431-050)(COMPLETED)

Phase 1

Completed

• Conditions: Type 2 Diabetes
• Interventions: Drug: sitagliptin phosphate

• Registration Number: NCT00975052
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

This study will determine the effect of concomitant administration of sitagliptin and metformin on post-meal incretin hormone concentrations in healthy adults.

Detailed Description

Not available

Study Timeline

• Study Start: 2006-01
• Primary Completion: 2006-03
• Study Completion: 2006-03
• Study First Submitted: 2009-09-10
• Study First Submitted QC: 2009-09-10
• Study First Posted: 2009-09-11
• Status Verified: 2015-08
• Last Update Submitted: 2015-08-18
• Last Update Posted: 2015-08-19

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 16

Inclusion Criteria

• Subject is in good health
• Subject has been a nonsmoker for at least 6 months
• Subject is willing to avoid strenuous activity from the screening visit until the end of the study
• Subject agrees not to consume grapefruit products during the study and to avoid all fruit juices 24 hours before and after study drug administration

Exclusion Criteria

• Any history of stroke or neurological disorder
• Subject has a history of cardiovascular, blood, endocrine or liver diseases
• Subject has a history of cancer

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
A	sitagliptin phosphate	Sitagliptin alone

Primary Outcome Measures

Name	Time	Method
Weighted average active GLP-1 (glucagonlike peptide-1) concentrations	4 hours after the postdose meal